Aller au contenu principal
2017 article

Intramuscular Administration of Placenta-Derived Stromal Cells Enhances Survival of Rhesus Macaque Monkeys Exposed to Total Body Irradiation

2Citations signalées — pas une note de qualité
3Institutions déclarées
2Pays d’affiliation déclarés

Résumé fourni par la source

Abstract Placenta-derived stromal cells named PLX-R18 have been shown in-vitro to secrete pro-hematopoiesis proteins, induce bone marrow migration, and promote colony formation. Murine in-vivo studies indicated that placental cells are capable of reducing lethality from the Hematopoietic Sub-syndrome of Acute Radiation Syndrome (HS-ARS). A NIAID-supported pilot study with non-human primate (NHP) rhesus macaque monkeys was conducted with the objective to characterize the effect of PLX-R18 on HS-ARS, including survival and hematological parameters in irradiated NHP. 62 male and female rhesus macaque monkeys were divided into irradiated and non-irradiated cohorts. Non-irradiated or irradiated NHPs were treated with three intramuscular doses of PLX-R18 at 1 and 5 days post irradiation, or with placebo control. All doses of PLX-R18 improved outcome of irradiated NHPs relative to placebo (dose of 4, 10 and 20M cells/kg increased survival by 33.3, 35.7 and 16.7% respectively). A tendency towards earlier recovery of blood lineages was evident in all doses tested, particularly, for the two lower doses. The 4 million cells/kg dose of PLX-R18 reduced the duration of critical neutropenia, thrombocytopenia, and anemia (NEUT Taken together, all doses of PLX-R18 positively affected survival rates and multiple hematological parameters of HS-ARS in rhesus monkeys and had no negative effects in either irradiated or non-irradiated monkeys. This supports the intended development of PLX-R18 as a treatment for HS-ARS. Disclosures Sher: Pluristem LTD: Employment, Equity Ownership. Prezma: Pluristem LTD: Employment, Equity Ownership. Fuchs-Telem: Pluristem LTD: Employment, Equity Ownership. Shraga- Heled: Pluristem LTD: Employment, Equity Ownership. Authier: CiToxLAB: Employment. Chang: SRI International: Employment. Ascah: CiToxLAB: Employment. Bakke: SRI International: Employment. Gahagen: SRI International: Employment. Ofir: Pluristem LTD: Employment, Equity Ownership.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

La source scientifique ouverte est momentanément indisponible.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Neonatal Respiratory Health ResearchMesenchymal stem cell researchEthics and Legal Issues in Pediatric Healthcare

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.